The story has been updated to include comments from Exact Sciences' conference call this morning.

NEW YORK (GenomeWeb) – Exact Sciences today reported no revenues for the second quarter as it awaits a decision from the US Food and Drug Administration on its Cologuard premarket approval submission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.